6.43% -0.0172

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX) 最新ニュース

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc (TOVX) 最新ニュース

Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 4.2% - Defense World

Get in on Theriva Biologics Inc's (TOVX) buy-in window today! – Sete News - SETE News

Theriva Biologics Inc [TOVX] moved down -7.55: Why It's Important – The DBT News - The DBT News

Closing Figures: Theriva Biologics Inc (TOVX)'s Negative Finish at 0.31, Down -7.55 – DWinneX - The Dwinnex

Stock Surge: Theriva Biologics Inc (TOVX) Closes at 0.33, Marking a -8.56 Increase/Decrease – DWinneX - The Dwinnex

FDA grants fast track status to Theriva's cancer drug By Investing.com - Investing.com Canada

Theriva™ Biologics anuncia la designación de vía rápida concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas metastásico

Theriva gets FDA fast track status for VCN-01 for pancreatic cancer (NYSE:TOVX) - Seeking Alpha

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - GlobeNewswire

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - Yahoo Finance

Sidoti's December Small-Cap Virtual Conference - The Globe and Mail

Another Biotech Stealing The Premarket Spotlight - The Globe and Mail

Theriva™ Biologics to Participate in the A.G.P. Virtual - GlobeNewswire

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - Yahoo Finance

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - Yahoo Finance

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024

Theriva Biologics: Q1 Earnings Snapshot - Houston Chronicle

Theriva Biologics Faces Liquidity Crisis: Urgent Capital Needed to Sustain Operations and Clinical Programs ... - TipRanks

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Yahoo Finance

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered ... - Yahoo Finance

Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial - TipRanks.com - TipRanks

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 ... - Yahoo Finance

Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy - TipRanks.com - TipRanks

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic ... - GlobeNewswire

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Diff - Benzinga

Theriva™ Biologics anuncia su presentación en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting - Yahoo Finance

Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript - Yahoo Finance

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript - Seeking Alpha

Theriva™ Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del ejercicio 2023

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and ... - Yahoo Finance

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could - Benzinga

Simtra BioPharma to invest $250m in US facility - Pharmaceutical Technology

Theriva Biologics Reports Positive Phase 2b Trial Progress - TipRanks.com - TipRanks

Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE ... - Yahoo Finance

Theriva Biologics participará en la Conferencia Anual de Oncología de B. Riley Securities

US dosing begins in Theriva's VIRAGE pancreatic cancer trial - Clinical Trials Arena

Theriva Biologics jumps on US FDA approval for pancreatic cancer treatment - Proactive Investors UK

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - Yahoo Finance

Theriva Biologics Appoints Ramon Alemany, Ph.D., as Senior Vice President of Discovery - citybiz

Theriva Biologics to Participate in Upcoming Investor Conferences - GlobeNewswire

Theriva Biologics Stock (AMEX:TOVX), Quotes and News Summary - Benzinga

Synthetic Biologics Rebrands as Theriva Biologics - Yahoo Finance

TOVXに似た銘柄